Advocacy and Your Bottom Line: How to Get Involved
Ophthalmology
Credits:
.75 AMA PRA Category 1 Credit(s) ™
.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 26, 2019
April 26, 2019
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Retina Specialists
Relevant Terms:
Step therapy, ASRS, AAO
David Eichenbaum, MD
Clinical Assistant Professor, Department of Ophthalmology
University of South Florida College of Medicine
Retina Vitreous Associates of Florida
Tampa, Florida
Ankoor R. Shah, MD
Retina Consultants of Houston - Vitreoretinal Surgery
Blanton Eye Institute - Methodist Hospital
Assistant Professor of Clinical Ophthalmology – Houston Methodist Institute for Academic Medicine
| 1. | Identify and Implement algorithms, decision-making tools, and patient communication approaches that can be used to determine the most appropriate treatment for the patient. | 2. | Identify opportunities to advocate against prior authorizations and step policies and appeal them. |
| 3. | Discuss the potential impact of the Drug Quality and Security Act and opportunities to advocate for continued access to compounded ophthalmologic drugs. | 4. | Describe the impact of the Medicare Access and CHIP Reauthorization Act (MACRA) on ophthalmology and its potential impact on the prescribing of anti-VEGF agents. |
| 1. | Identify and Implement algorithms, decision-making tools, and patient communication approaches that can be used to determine the most appropriate treatment for the patient. |
| 2. | Identify opportunities to advocate against prior authorizations and step policies and appeal them. |
| 3. | Discuss the potential impact of the Drug Quality and Security Act and opportunities to advocate for continued access to compounded ophthalmologic drugs. |
| 4. | Describe the impact of the Medicare Access and CHIP Reauthorization Act (MACRA) on ophthalmology and its potential impact on the prescribing of anti-VEGF agents. |
Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Grantor Statement
Supported through an educational grant from Regeneron Pharmaceuticals, Inc.
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
•David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Allergan plc; Genentech; Notal Vision; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Alcon/Novartis; Allergan plc.; Clearside Biomedical; Genentech; and Opthotech. Speaker’s Bureau: Allergan plc; Genentech; and Notal Vision. Stock/Shareholder: BIRC, Clearside Biomedical; Humera; and US Retina.
•Ankoor R. Shah, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Allergan.
•Sean Goodale, CPA, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AAOE, Genentech, Novartis, and Regeneron Pharmaceuticals. Speakers Bureau: Genentech and Regeneron Pharmaceuticals.
•Editorial Support Disclosures, Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, Evolve; and Debra Gordon, MS, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
